Experienced in Felty Syndrome

Dr. Steven J. Klein

Rheumatology
Klein And Associates MD PA
346 Mill St, 
Hagerstown, MD 
Accepting New Patients
Experienced in Felty Syndrome
Klein And Associates MD PA
346 Mill St, 
Hagerstown, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Klein is a Rheumatologist in Hagerstown, Maryland. Dr. Klein is rated as an Experienced provider by MediFind in the treatment of Felty Syndrome. His top areas of expertise are Axial Spondyloarthritis (AxSpA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis, and Postmenopausal Osteoporosis. Dr. Klein is currently accepting new patients.

His clinical research consists of participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in MD
Hospital Affiliations
Wellspan Waynesboro Hospital
Western Maryland Regional Medical Center
Wellspan Chambersburg Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

KLEIN AND ASSOCIATES MD PA
346 Mill St, Hagerstown, MD 21740
Other Locations
MERITUS MEDICAL CENTER INC
11110 Medical Campus Rd, Hagerstown, MD 21742

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee
A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Biological, Drug
Study Drug: Amniotic Fluid
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Genetic
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Combination product
Study Drugs: Abaloparatide solid microstructured transdermal system, Abaloparatide subcutaneous
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials
Similar Doctors
Advanced in Felty Syndrome
Dr. Dima F. Nimri
Rheumatology
Advanced in Felty Syndrome
Dr. Dima F. Nimri
Rheumatology

Medical Faculty Associates, Inc

2300 M St Nw, 
Washington, DC 
 (61.8 miles away)
202-677-6990
Languages Spoken:
English
See accepted insurances

Dima Nimri is a Rheumatologist in Washington, Washington, D.c.. Dr. Nimri is rated as an Experienced provider by MediFind in the treatment of Felty Syndrome. Her top areas of expertise are Felty Syndrome, Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE), and Splenectomy.

Experienced in Felty Syndrome
Dr. Debbie S. Litman
Rheumatology
Experienced in Felty Syndrome
Dr. Debbie S. Litman
Rheumatology

Suburban/nrh Medical Rehabilitation Inc

6410 Rockledge Dr, Suite 600, 
Bethesda, MD 
 (52.5 miles away)
Languages Spoken:
English
See accepted insurances

Debbie Litman is a Rheumatologist in Bethesda, Maryland. Dr. Litman is rated as an Advanced provider by MediFind in the treatment of Felty Syndrome. Her top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Melorheostosis, and Melorheostosis with Osteopoikilosis.

Experienced in Felty Syndrome
Dr. Stamatina J. Danielides
Rheumatology
Experienced in Felty Syndrome
Dr. Stamatina J. Danielides
Rheumatology

Inova Medical Group - Rheumatology

Ashburn, VA 
 (42.9 miles away)
703-554-1133
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stamatina Danielides is a Rheumatologist in Ashburn, Virginia. Dr. Danielides is rated as an Advanced provider by MediFind in the treatment of Felty Syndrome. Her top areas of expertise are Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Juvenile Temporal Arteritis, Temporal Arteritis, and Colonoscopy. Dr. Danielides is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klein's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile